| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a693232b92910547c898db10feb83fef |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate |
2012-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbc7b1e20cf957c67029f6bdd7a897cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9986dc023307cbd5cb83c3f934607a2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_161a8b9f31f7a12c1620d7cb83317602
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9a9bcee3f1c1c89ac947d826dffcf65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a699c5a422f6280be3f713ba5838e7b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0ef7b16984727f48bc8245246fa8f35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34bb0316593a0d3bebaf248c621c2858 |
| publicationDate |
2017-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9643970-B2 |
| titleOfInvention |
Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors |
| abstract |
This invention is directed to compounds, which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I) n nThe present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019226944-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11608342-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11028092-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10934294-B2 |
| priorityDate |
2011-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |